3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
5
Thoracic
1
Sarcoma
1
Gastrointestinal
1
Dermatologic
1
Conditions
Melanoma
5
Uterine Cervical Neoplasms
1
Thymoma
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Noonan Syndrome 6
1
Glioblastoma
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Brain Neoplasms
1
Astrocytoma
1
Interventions
pembrolizumab
28
Cyclophosphamide
14
Nivolumab
13
Paclitaxel
7
fludarabine
6
Specimen Handling
5
aldesleukin
4
Taxes
4
Ipilimumab
4
Interleukin-2
4
Gemcitabine
4
Drug Therapy
4
Docetaxel
4
Carboplatin
4
Bevacizumab
4
poly ICLC
3
liposomal doxorubicin
3
epacadostat
3
cobimetinib
3
cemiplimab
3
Magnetic Resonance Spectroscopy
3
Injections
3
Cisplatin
3
veliparib
2
ulixertinib
2
sargramostim
2
pertuzumab
2
pegilodecakin
2
pazopanib
2
osimertinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
regorafenib
×
Dermatologic
×
Clear all
NCT02307500
2022-09-10
RESOUND
Istituto Clinico Humanitas
Phase 2
Completed
82 enrolled